TransMedics(TMDX) Newsfilter·2025-03-15 13:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against TransMedics Group, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 15, 2025 [2][4]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics and its executives made false and misleading statements, failing to disclose practices such as kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [4]. - It is claimed that TransMedics engaged in unsafe practices and concealed safety issues, leading to increased scrutiny and regulatory risks [4]. - The lawsuit asserts that the misleading statements about the company's business and operations resulted in investor damages when the true details became public [4]. Group 2: Market Reaction - Following the release of a report by Scorpion Capital on January 10, 2025, which described TransMedics as a significant healthcare fraud, the company's stock fell by 5.15% on that day [5][6]. - The stock experienced an additional decline of 6.9% on January 13, 2025, indicating a negative market reaction to the allegations [6]. Group 3: Legal Proceedings - Investors who purchased securities in TransMedics between February 23, 2023, and January 10, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].